# US 2001/0056062 A1 · Peritoneal dialysis solutions with polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0056062 A1
- Document ID: US20010056062A1
- Status: Published application
- Kind: A1
- Application number: 09/909,733
- Filed: 2001-07-20
- Published: 2001-12-27
- Earliest claimed: 1992-12-22
- Assignees: Baxter International Inc.
- Inventors: Leo Martis; Ron Burke; Dirk Faict
- Web page: https://patentgrep.com/patent/US20010056062A1

## CPC

- A61K 38/018: {from milk}
- A61K 38/02: Peptides of undefined number of amino acids; Derivatives thereof
- A61M 1/287: {Dialysates therefor}
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides an improved dialysis solution. The improved dialysis solution provides for the use of specific polypeptides as an osmotic agent with an additional osmotic agent such as dextrose. To this end, the present invention provides, in an embodiment, a peritoneal dialysis solution comprising as osmotic agents approximately 0.25 to about 4.0% (w/v) polypeptides and approximately 0.5% to about 4.0% (w/v) dextrose. The polypeptides have well defined characteristics.

## Claims

### Claim 1

A peritoneal dialysis solution comprising as osmotic agents approximately 0.25 to about 4.0% by weight of synthetic polypeptides wherein the synthetic peptides are approximately 2 to about 15 amino acids long.

### Claim 2

A two part peritoneal dialysis solution designed to be mixed prior to infusion into a patient comprising:
a first part housed in a first structure including approximately 1.0 to about 8% (w/v) dextrose and a pH of approximately 4.0 to about 5.5;
a second part housed in a second structure including approximately 0.5 to about 8.0% (w/v) polypeptides and a pH of approximately 6.0 to about 7.5; and
including in either the first or the second structure a sufficient amount of the following ingredients so when the first part and second part are mixed, the following is provided: 120 to about 150 (mEq/L) sodium; 80.0 to about 110.0 (mEq/L) chloride; 0.0 to about 5.0 (mEq/L) lactate; 0.0 to about 45.0 (mEq/L) bicarbonate; 0.0 to about 4.0 (mEq/L) calcium; and 0.0 to about 4.0 (mEq/L) magnesium.

### Claim 3 (depends on 2)

The two part peritoneal dialysis solution of claim 2 wherein the first and second structures are two separate chambers of a single container.

### Claim 4 (depends on 2)

The two part peritoneal dialysis solution of claim 2 wherein the pH of a resultant solution, comprising a mixture of the first part and the second part, is approximately 6.0 to about 7.4.

### Claim 5 (depends on 2)

The two part peritoneal dialysis solution of claim 2 wherein the molecular weight average of the polypeptides is approximately 400 to about 900 daltons.

### Claim 6 (depends on 2)

The two part peritoneal dialysis solution of claim 2 wherein the polypeptides comprise:
not more than approximately 0.10% of the polypeptides having a molecular weight of greater than 1200;
not more than approximately 25% of the polypeptides having a molecular weight of less than 400; and
the weight average of polypeptides being within the range of approximately 400 to about 900 daltons.

### Claim 7 (depends on 2)

The two part peritoneal dialysis solution of claim 2 wherein the polypeptides include synthetic polypeptides.

### Claim 8 (depends on 2)

The two part peritoneal dialysis solution of claim 2 wherein the synthetic polypeptides are approximately 2 to about 15 amino acids long.

### Claim 9

An intraperitoneal drug delivery solution comprising approximately 0.25 to about 4.0% (w/v) polypeptides.

### Claim 10 (depends on 9)

The intraperitoneal drug delivery solution of claim 9 wherein the molecular weight average of the polypeptides is approximately 400 to about 900 daltons.

### Claim 11 (depends on 9)

The intraperitoneal drug delivery solution of claim 9 wherein the polypeptides comprise:
not more than approximately 0.10% of the polypeptides having a molecular weight of greater than 1200;
not more than approximately 25% of the polypeptides having a molecular weight of less than 400; and
the weight average of polypeptides being within the range of approximately 400 to about 900 daltons.

### Claim 12

A peritoneal dialysis solution comprising as osmotic agent:
a synthetic polypeptide mixture having an average molecular weight of approximately 400 to about 900 daltons.

### Claim 13 (depends on 12)

The peritoneal dialysis solution of claim 12 wherein the osmotic agent includes dextrose.

### Claim 14 (depends on 12)

The peritoneal dialysis solution of claim 12 wherein the solution includes:
approximately 120.00 to about 150.00 (mEq/L) of sodium; and
approximately 80.0 to about 110.0 (mEq/L) of chloride.

### Claim 15 (depends on 12)

The peritoneal dialysis solution of claim 12 wherein the solution includes each of sodium, chloride, lactate, bicarbonate, calcium, and magnesium.

### Claim 16 (depends on 12)

The peritoneal dialysis solution of claim 12 wherein the solution includes:
0 to about 45.00 (mEq/L) of lactate;
0 to about 45.00 (mEq/L) of bicarbonate;
0 to about 45.00 (mEq/L) of calcium; and
0 to about 45.00 (mEq/L) of magnesium.

### Claim 17 (depends on 12)

The peritoneal dialysis solution of claim 12 wherein the pH of the solution is approximately 6.0 to about 7.4.

### Claim 18 (depends on 12)

The peritoneal dialysis solution of claim 12 wherein the synthetic peptides are approximately 2 to about 15 amino acids long.
